Fundamental Analysis of ELIEM THERAPEUTICS INC(NASDAQ:ELYM) stock

Fundamental Rating

Overall ELYM gets a fundamental rating of 3 out of 10. We evaluated ELYM against 568 industry peers in the Biotechnology industry. ELYM has a great financial health rating, but its profitability evaluates not so good. ELYM does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ELYM had negative earnings in the past year.

ELYM had a positive operating cash flow in the past year.

ELYM had negative earnings in each of the past 5 years.

ELYM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ELYM has a better Return On Assets (-28.40%) than 70.77% of its industry peers.

With an excellent Return On Equity value of -28.88%, ELYM belongs to the best of the industry, outperforming 80.11% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-28.4%
ROE	-28.88%
ROIC	N/A

ROA(3y)-31.78%

ROA(5y)-44.63%

ROE(3y)-32.97%

ROE(5y)-48.21%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELYM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ELYM has more shares outstanding than it did 1 year ago.

ELYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 53.84 indicates that ELYM is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 53.84, ELYM belongs to the best of the industry, outperforming 98.06% of the companies in the same industry.

There is no outstanding debt for ELYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	53.84

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ELYM has a Current Ratio of 60.41. This indicates that ELYM is financially healthy and has no problem in meeting its short term obligations.

ELYM has a better Current ratio (60.41) than 100.00% of its industry peers.

ELYM has a Quick Ratio of 60.41. This indicates that ELYM is financially healthy and has no problem in meeting its short term obligations.

ELYM has a better Quick ratio (60.41) than 100.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	60.41
Quick Ratio	60.41

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ELYM have decreased strongly by -27.15% in the last year.

EPS 1Y (TTM)-27.15%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-851.87%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ELYM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.41% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y60%

EPS Next 2Y23.41%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ELYM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELYM. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ELYM's earnings are expected to grow with 23.41% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y23.41%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ELYM!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ELIEM THERAPEUTICS INC

NASDAQ:ELYM (10/2/2024, 8:06:17 PM)

After market: 5.1 -0.01 (-0.2%)

5.11

-0.05 (-0.97%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-04 2024-03-04/amc

Earnings (Next)N/A N/A

Inst Owners84.1%

Inst Owner Change13%

Ins Owners7.95%

Ins Owner Change-6.88%

Market Cap342.68M

Analysts43.33

Price Target4.59 (-10.18%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	6230.48
P/B	1.54
P/tB	1.54
EV/EBITDA	N/A

EPS(TTM)-2.15

EYN/A

EPS(NY)-0.63

Fwd EYN/A

FCF(TTM)-0.07

FCFYN/A

OCF(TTM)0

OCFY0.02%

SpS0

BVpS3.31

TBVpS3.31

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-28.4%
ROE	-28.88%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-31.78%

ROA(5y)-44.63%

ROE(3y)-32.97%

ROE(5y)-48.21%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score7

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	60.41
Quick Ratio	60.41
Altman-Z	53.84

F-Score7

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-27.15%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-851.87%

EPS Next Y60%

EPS Next 2Y23.41%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-110.49%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y89.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y100.12%

OCF growth 3YN/A

OCF growth 5YN/A

ELIEM THERAPEUTICS INC (ELYM)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens